Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

February 28, 2009

Conditions
Neoplasms
Interventions
DRUG

Nexavar (Sorafenib, BAY43-9006)

The purpose of this study is to: 1)evaluate how your body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2) measure your blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3) to determine the safety of sorafenib.

Trial Locations (2)

06511-5991

New Haven

78229-3307

San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY